์ด ์„ธ์…˜์— ๋Œ€ํ•œ ๊ธฐ๋ณธ ์„ค์ •์ด ์—…๋ฐ์ดํŠธ๋˜์—ˆ์Šต๋‹ˆ๋‹ค. ๊ณ ๊ฐ๋‹˜์˜ ๊ณ„์ • ์„ค์ •์„ ์˜๊ตฌ์ ์œผ๋กœ ๋ณ€๊ฒฝํ•˜๋ ค๋ฉด ๋‚ด ๊ณ„์ •์œผ๋กœ ์ด๋™ํ•˜์„ธ์š”.
์›ํ•˜๋Š” ์ˆ˜๋ น ๊ตญ๊ฐ€ ๋˜๋Š” ์‚ฌ์šฉ ์–ธ์–ด๋ฅผ ๋‚ด ๊ณ„์ •์—์„œ ์–ธ์ œ๋“ ์ง€ ์—…๋ฐ์ดํŠธํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
> beauty2 heart-circle sports-fitness food-nutrition herbs-supplements pageview
클릭하여 iHerb 접근성 정책 보기
₩40,000 이상 주문 시 무료배송
iHerb 앱
checkoutarrow
KR

사프란: 자연적으로 정신건강을 증진하는 방법

42,760 조회수

anchor-icon 목차 dropdown-icon
anchor-icon 목차 dropdown-icon

๊ธฐ์กด์˜ ์ฃผ๋ฅ˜ ์น˜๋ฃŒ๋ฒ•์˜ ํ•œ๊ณ„๋Š” ๊ทผ๊ฑฐ์— ๊ธฐ๋ฐ˜ํ•œ ๋ณด์™„ ์น˜๋ฃŒ์™€ ๋Œ€์•ˆ ์น˜๋ฃŒ(CAM) ๋ฐฉ๋ฒ•์„ ํ•„์š”๋กœ ํ•ฉ๋‹ˆ๋‹ค.

์ •์‹  ์งˆํ™˜์„ ์น˜๋ฃŒํ•˜๋Š” ๋‹ค์–‘ํ•œ ์•ฝ๋ฌผ์€ ๊ทธ ํšจ๊ณผ๊ฐ€ ์ œํ•œ์ ์ด๊ณ , ์•ˆ์ „์„ฑ์—๋„ ๋ฌธ์ œ๊ฐ€ ์žˆ์œผ๋ฉฐ, ๋น„์šฉ๋„ ๋†’๋‹ค๋Š” ๋‹จ์ ์ด ์žˆ์–ด ๋”์šฑ ์•ˆ์ „ํ•˜๊ณ  ํšจ๊ณผ์ ์ด๋ฉฐ ์ €๋ ดํ•œ ์น˜๋ฃŒ๊ฐ€ ์‹œ๊ธ‰ํ•œ ๊ณผ์ œ๋กœ ๋Œ€๋‘๋˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ˆ˜์‹ญ ๋…„๊ฐ„์˜ ์—ฐ๊ตฌ์™€ ์ˆ˜์‹ญ์–ต ๋‹ฌ๋Ÿฌ์˜ ์‚ฐ์—… ์ž๊ธˆ ์ง€์›์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ์ฃผ์š” ์šฐ์šธ์ฆ๊ณผ ์–‘๊ทน์„ฑ ์žฅ์• , ์กฐํ˜„๋ณ‘์„ ๋น„๋กฏํ•œ ์—ฌํƒ€์˜ ์ •์‹  ์งˆํ™˜์— ๋„๋ฆฌ ์‚ฌ์šฉ๋˜๋Š” ์•ฝ๋ฌผ์น˜๋ฃŒ์˜ ํšจ๊ณผ๋ฅผ ๋’ท๋ฐ›์นจํ•˜๋Š” ์ฆ๊ฑฐ๋Š” ๊ทธ๋ฆฌ ์‹ ๋น™์„ฑ์ด ๋†’์ง€ ์•Š์Šต๋‹ˆ๋‹ค. ์ด๋กœ ์ธํ•˜์—ฌ ๋”์šฑ๋” ๋งŽ์€ ์ •์‹  ์งˆํ™˜ ํ™˜์ž๋“ค์€ ํ•œ์˜์‚ฌ๋‚˜ ์ž์—ฐ ์š”๋ฒ• ์˜์‚ฌ, ํ—ˆ๋ธŒ ์ „๋ฌธ๊ฐ€๋‚˜ ์ฒ™์ถ” ์ง€์••์‚ฌ, ๋™์ข… ์š”๋ฒ• ์˜์‚ฌ ๋“ฑ์„ ํ†ตํ•ด ๋ณด์™„ ์น˜๋ฃŒ์™€ ๋Œ€์•ˆ ์น˜๋ฃŒ(CAM)๋ฅผ ์ฐพ๊ณ  ์žˆ๋Š” ์‹ค์ •์ž…๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ํ†ตํ•ฉ ์ •์‹  ๊ฑด๊ฐ• ๊ด€๋ฆฌ์— ๋Œ€ํ•œ ๊ด€์‹ฌ์ด ์ฆ๊ฐ€ํ•จ์— ๋”ฐ๋ผ ์‚ฌํ”„๋ž€ ์—ญ์‹œ ๋‹ค์–‘ํ•œ ์‹ ๊ฒฝ ์ •์‹  ์งˆํ™˜์„ ์น˜๋ฃŒํ•˜๋Š” ์œ ๋งํ•œ ์ ‘๊ทผ ๋ฐฉ๋ฒ•์œผ๋กœ ๋ถ€์ƒํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

๋‹ค์–‘ํ•œ ์‹ ๊ฒฝ ์ •์‹  ์งˆํ™˜ ์น˜๋ฃŒ์— ์ข‹์€ ์‚ฌํ”„๋ž€

์‚ฌํ”„๋ž€(Crocus sativus)์€ ๊ณ ๋Œ€ ํŽ˜๋ฅด์‹œ์•„์™€ ์ค‘๊ตญ์—์„œ ์ •๋ ฅ์ œ์™€ ์ง„ํ•ด ๊ฑฐ๋‹ด์ œ, ํ•ญ๊ฒฝ๋ จ์ œ์™€ ๋ฐฉ๋ถ€์ œ ๋ฐ ์ธ์ง€ ์ฆ์ง„ ์•ฝ์ œ๋กœ ์˜ค๋žซ๋™์•ˆ ์• ์šฉ๋˜์–ด ์˜จ ์‹๋ฌผ์ž…๋‹ˆ๋‹ค. ์‚ฌํ”„๋ž€์ด ์šฐ์šธ์ฆ๊ณผ ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜, ๊ทธ๋ฆฌ๊ณ  ์ฃผ์˜๋ ฅ ๊ฒฐํ• ๊ณผ์ž‰ ํ–‰๋™ ์žฅ์•  (ADHD)์— ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค๋Š” ์‚ฌ์‹ค์€ ์ธ๊ฐ„์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์˜ค๋žœ ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•ด ์ถฉ๋ถ„ํžˆ ์ž…์ฆ๋œ ๋ฐ” ์žˆ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ, ์‚ฌํ”„๋ž€์ด ๋ถˆ์•ˆ ์žฅ์• ์™€ ์กฐํ˜„๋ณ‘, ๊ทธ๋ฆฌ๊ณ  ๊ฐ•๋ฐ• ์žฅ์• (OCD)์—๋„ ํšจ๊ณผ์ ์ด๋ผ๋Š” ์‚ฌ์‹ค์€ ๋™๋ฌผ ์‹คํ—˜์„ ํ†ตํ•ด ๋ฐํ˜€์ง€๊ธฐ๋„ ํ–ˆ์Šต๋‹ˆ๋‹ค. ์‚ฌํ”„๋ž€์˜ ์ƒ๋ฆฌ ํ™œ์„ฑ ๋ฌผ์งˆ์€ ๋„ํŒŒ๋ฏผ๊ณผ ๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ์˜ ์žฌํก์ˆ˜ ์–ต์ œ ์ž‘์šฉ์„ ์ฆ์ง„์‹œํ‚ฌ ์ˆ˜ ์žˆ์œผ๋ฉฐ, N-๋ฉ”ํ‹ธ D-์•„์ŠคํŒŒ๋ฅดํŠธ์‚ฐ(NMDA) ์ˆ˜์šฉ์ฒด ๊ธธํ•ญ์ œ์™€ GABA ์ž‘์šฉ์ œ๋กœ์˜ ๊ธฐ๋Šฅ๋„ ๋ฐœํœ˜ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ด๋ฒˆ ๋ธ”๋กœ๊ทธ๋Š” ์šฐ์šธ์ฆ๊ณผ ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜(AD), ๊ทธ๋ฆฌ๊ณ  ์ฃผ์˜๋ ฅ ๊ฒฐํ• ๊ณผ์ž‰ ํ–‰๋™ ์žฅ์• (ADHD)์— ๋Œ€ํ•œ ์‚ฌํ”„๋ž€์˜ ํšจ๊ณผ์— ๋Œ€ํ•œ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ์— ๋Œ€ํ•ด ๊ฐ„๋‹จํ•˜๊ฒŒ ์•Œ๋ ค๋“œ๋ฆฌ๋„๋ก ํ•˜๊ฒ ์Šต๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€๊ณผ ์šฐ์šธ์ฆ

์‚ฌํ”„๋ž€์˜ ์šฐ์šธ์ฆ ์น˜๋ฃŒ ํšจ๊ณผ๋Š” ์„ธ๋กœํ† ๋‹Œ ํšจ๊ณผ์™€, ํ•ญ์‚ฐํ™”์ œ ํšจ๊ณผ๋ฅผ ๋น„๋กฏํ•œ ์†Œ์—ผ ํšจ๊ณผ์™€ ์‹ ๊ฒฝ ๋‚ด๋ถ„๋น„ ํšจ๊ณผ ์‹ ๊ฒฝ ๋ณดํ˜ธ ๋“ฑ ์—ฌ๋Ÿฌ ๋ฉ”์ปค๋‹ˆ์ฆ˜์— ๊ธฐ์ธํ•ฉ๋‹ˆ๋‹ค. ๊ฐ€๋ฒผ์šด ์šฐ์šธ์ฆ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ์‚ฌํ”„๋ž€์˜ ํšจ๊ณผ๋ฅผ ์กฐ์‚ฌํ•œ 6๊ฑด์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ์ฒด๊ณ„์ ์œผ๋กœ ์กฐ์‚ฌํ•œ ๊ฒฐ๊ณผ, ์‚ฌํ”„๋ž€์€ ๊ธฐ์กด์˜ ํ•ญ์šฐ์šธ ์น˜๋ฃŒ์ œ์™€ ๋น„์Šทํ•œ ํšจ๋Šฅ์„ ๋‚˜ํƒ€๋‚ธ๋‹ค๋Š” ๊ฒฐ๋ก ์„ ๋‚ด๋ ธ์Šต๋‹ˆ๋‹ค. 2019๋…„์— ๋ฐœํ‘œ๋œ ๋ฉ”ํƒ€ ๋ถ„์„ ์—ญ์‹œ, ๊ฐ€๋ฒผ์šด ์ •๋„์—์„œ ์ค‘์ฆ ์ •๋„์˜ ์šฐ์šธ์ฆ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ 11๊ฑด์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ์กฐ์‚ฌํ•˜์—ฌ (์ดํ™˜์ž ์ˆ˜ > 500), ์‚ฌํ”„๋ž€์ด ์œ„์•ฝ๋ณด๋‹ค ํ†ต๊ณ„์ ์œผ๋กœ ์›”๋“ฑํ•œ ํšจ๊ณผ๋ฅผ ๋ณด์ด๋ฉฐ, (ํ”Œ๋ฃจ์˜ฅ์„ธํ‹ด, ์‹œํƒˆ๋กœํ”„๋žŒ๊ณผ ๊ฐ™์€) SSRI ํ•ญ์šฐ์šธ์ œ์™€ ๋™๋“ฑํ•œ ํšจ๊ณผ๋ฅผ ๋ฐœํœ˜ํ•œ๋‹ค๋Š” ๊ฒฐ๋ก ์„ ๋‚ด๋ ธ์Šต๋‹ˆ๋‹ค. ์‚ฌํ”„๋ž€์€ (ํ•˜๋ฃจ 1.5 mg๊นŒ์ง€์˜) ๋†’์€ ๋†๋„๋กœ ํˆฌ์•ฝํ•œ ๊ฒฝ์šฐ์—๋„ ์œ„์•ฝ๊ณผ ๋น„๊ตํ•˜์—ฌ ๋šœ๋ ทํ•œ ๋ถ€์ž‘์šฉ์„ ๋‚˜ํƒ€๋‚ด์ง€ ์•Š์•˜๋‹ค๊ณ  ํ•ฉ๋‹ˆ๋‹ค. ๋ฉ”ํƒ€ ๋ถ„์„์„ ํฌํ•จํ•œ ๋ชจ๋“  ์—ฐ๊ตฌ๋Š” ์ „ํ†ต์ ์œผ๋กœ ์‚ฌํ”„๋ž€์„ ์šฐ์šธ์ฆ์„ ๋น„๋กฏํ•œ ๋‹ค์–‘ํ•œ ์˜๋ฃŒ ์งˆํ™˜์— ํ™œ์šฉํ•ด์˜จ ์ด๋ž€์—์„œ ์ด๋ฃจ์–ด์กŒ์Šต๋‹ˆ๋‹ค. ๋‚˜์•„๊ฐ€, ์—ฐ๊ตฌ ๋Œ€์ƒ ํ™˜์ž๋“ค ์ค‘ ๋งŽ์€ ๊ฒฝ์šฐ๋Š” ๋™๋ฐ˜ ์งˆํ™˜์„ ๊ฐ€์ง€๊ณ  ์žˆ๊ธฐ๋„ ํ–ˆ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๋‘ ๊ฐ€์ง€ ์š”์ธ์œผ๋กœ ์ธํ•ด ์—ฐ๊ตฌ ๊ฒฐ๊ณผ์˜ ํŽธํ–ฅ์„ฑ์„ ๋ฐฐ์ œํ•  ์ˆ˜๋Š” ์—†์Šต๋‹ˆ๋‹ค. ๋”ฐ๋ผ์„œ ๋…๋ฆฝ ์—ฐ๊ตฌ ๊ธฐ๊ด€์—์„œ ์‹œํ–‰ํ•˜๋Š” ๋Œ€๊ทœ๋ชจ์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•ด ์ด๋Ÿฌํ•œ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ํ™•์ธํ•˜๊ณ  ์ตœ์ ์˜ ์šฉ๋Ÿ‰๊ณผ ์น˜๋ฃŒ ๊ธฐ๊ฐ„ ๋“ฑ์„ ํ™•๋ฆฝํ•ด์•ผ ํ•  ํ•„์š”๊ฐ€ ์žˆ์Šต๋‹ˆ๋‹ค. ์ตœ๊ทผ์—๋Š” (๊ฐ•ํ™ฉ์—์„œ ์ถ”์ถœํ•œ) ์ปคํ๋ฏผ๋„ ๋‹จ๋…์œผ๋กœ ๋ณต์šฉํ•˜๊ฑฐ๋‚˜ ๋‹ค๋ฅธ ์•ฝ๋ฌผ์˜ ๋ณด์กฐ์ œ๋กœ ๋ณต์šฉํ•  ๊ฒฝ์šฐ, ํ•ญ์šฐ์šธ ํšจ๊ณผ๋ฅผ ๋ณด์ธ๋‹ค๋Š” ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋„ ๋ฐœํ‘œ๋˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ, ์ด๋Ÿฌํ•œ ์ปคํ๋ฏผ๊ณผ ์‚ฌํ”„๋ž€์„ ๋ณ‘์šฉํ•  ๊ฒฝ์šฐ, ์šฐ์šธ์ฆ ์น˜๋ฃŒ์— ์‹œ๋„ˆ์ง€ ํšจ๊ณผ๋ฅผ ๋ฐœํœ˜ํ•  ์ˆ˜ ์žˆ๋‹ค๋Š” ์ œ์•ˆ๋„ ์žˆ์—ˆ์Šต๋‹ˆ๋‹ค. ์ด์ค‘ ๋งน๊ฒ€ ๋ฐฉ๋ฒ•์œผ๋กœ ์ง„ํ–‰๋œ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์‹œํ—˜์—์„œ, ์ฃผ์š” ์šฐ์šธ์ฆ ํ™˜์ž๋ฅผ ์„ ๋ฐœํ•˜์—ฌ ๋ฌด์ž‘์œ„๋กœ ์ €์šฉ๋Ÿ‰์˜ ์ปคํ๋ฏผ ์ถ”์ถœ๋ฌผ (250mg BID)๊ณผ ๊ณ ์šฉ๋Ÿ‰์˜ ์ปคํ๋ฏผ ์ถ”์ถœ๋ฌผ (500mg BID) ๋˜๋Š” ์ €์šฉ๋Ÿ‰์˜ ์ปคํ๋ฏผ๊ณผ ์‚ฌํ”„๋ž€ (15mg BID)์„ ๋ณ‘์šฉํ•˜์—ฌ ํˆฌ์•ฝํ•œ ๊ฒฐ๊ณผ, ์œ„์•ฝ๋งŒ์„ ํˆฌ์•ฝํ•œ ๋Œ€์กฐ๊ตฐ์— ๋น„ํ•ด ์šฐ์šธ์ฆ์ด ์›”๋“ฑํžˆ ๊ฐœ์„ ๋œ ๊ฒฐ๊ณผ๋ฅผ ๋ณด์˜€์Šต๋‹ˆ๋‹ค. ๋ฌผ๋ก  ์ด๋Ÿฌํ•œ ์‹๋ฌผ์„ฑ ์•ฝ์žฌ์˜ ์šฉ๋Ÿ‰์— ๋”ฐ๋ผ ์šฐ์šธ์ฆ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋‹ฌ๋ฆฌ ๋‚˜ํƒ€๋‚˜๋Š”์ง€์— ๋Œ€ํ•ด์„œ๋Š” ๋” ๋งŽ์€ ์—ฐ๊ตฌ๊ฐ€ ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€ ์‹๋ฌผ์ธ C. Sativus์˜ ์žฌ๋ฐฐ ๋ฐ ์ˆ˜ํ™•์€ ๋…ธ๋™ ์ง‘์•ฝ์ ์ด์–ด์„œ ์‚ฌํ”„๋ž€์„ ์ฑ„์ทจํ•˜๋ ค๋ฉด ์ˆ˜์ฒœ ์†ก์ด์˜ ๊ฝƒ์—์„œ ์ˆ˜๋ฐฑ ์‹œ๊ฐ„์— ๊ฑธ์ณ ์ผ์ผ์ด ์‚ฌ๋žŒ ์†์œผ๋กœ ์•”์ˆ ์„ ์ฑ„์ทจํ•ด์•ผ ํ•ฉ๋‹ˆ๋‹ค. ๋”ฐ๋ผ์„œ ์„ธ๊ณ„์ ์œผ๋กœ๋„ ๊ณ ํ’ˆ์งˆ์˜ ์‚ฌํ”„๋ž€์€ ๊ท€ํ•˜๊ณ  ๊ทธ ๊ฐ’๋„ ๋น„์Œ‰๋‹ˆ๋‹ค. ๋”ฐ๋ผ์„œ, C. Sativus ์ƒ์‚ฐ์„ฑ์„ ๋†’์ด๊ณ  ๊ฐ€๊ฒฉ์„ ๋ณด๋‹ค ์ €๋ ดํ•˜๊ฒŒ ํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ๊ณผํ•™์ž๋“ค์€ C. Sativus์˜ ์•Œ๋ฟŒ๋ฆฌ์—์„œ ๋‹ค์–‘ํ•œ ํ™œ์„ฑ ์„ฑ๋ถ„์„ ์ถ”์ถœํ•˜์—ฌ ์šฐ์šธ์ฆ ์ฆ์ƒ์„ ๋ณด์ด๋Š” ์ฅ์— ํˆฌ์—ฌํ•œ ํ›„, ๊ทธ ํšจ๊ณผ๋ฅผ ์กฐ์‚ฌํ–ˆ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์—ฐ๊ตฌ๋กœ๋ถ€ํ„ฐ C. Sativus์˜ ์•”์ˆ ์ธ ์‚ฌํ”„๋ž€๊ณผ ๋™์ผํ•œ ํ•ญ์šฐ์šธ ํšจ๊ณผ๋ฅผ ๋ณด์ด๋Š” ๋‘ ๊ฐ€์ง€ ์ƒ๋ฆฌ ํ™œ์„ฑ ์„ฑ๋ถ„์„ ์ฐพ์•„๋‚ด์—ˆ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์„ฑ๋ถ„์˜ ์•ฝํšจ๋ฅผ ํ™•์ธํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์šฐ์šธ์ฆ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์—ฐ๊ตฌ๊ฐ€ ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€๊ณผ ADHD

ADHD ์น˜๋ฃŒ์— ๋„๋ฆฌ ์‚ฌ์šฉ๋˜๋Š” ๋ฉ”ํ‹ธํŽ˜๋‹ˆ๋ฐ์ดํŠธ(methylphenidate)๋ฅผ ๋น„๋กฏํ•œ ์—ฌ๋Ÿฌ ์ž๊ทน์ œ๋Š” ๋ถˆ๋ฉด์ฆ๊ณผ ์‹์š• ๊ฐ์†Œ ๋ฐ ๋ณตํ†ต๊ณผ ๊ฐ™์€ ๋ถ€์ž‘์šฉ์„ ์ผ์œผํ‚ต๋‹ˆ๋‹ค. ์ž๊ทน์ œ๋ฅผ ๋น„๋กฏํ•˜์—ฌ ์„ฑ์ธ ADHD ํ™˜์ž์˜ ์•ฝ๋ฌผ์น˜๋ฃŒ์— ์‚ฌ์šฉ๋˜๋Š” ์—ฌ๋Ÿฌ ์•ฝ๋ฌผ์€ ์–ด๋ฆฐ์ด ADHD ํ™˜์ž์— ๋Œ€ํ•œ ์•ฝ๋ฌผ์น˜๋ฃŒ์— ๋น„ํ•ด ๊ทธ ํšจ๊ณผ๊ฐ€ ์ ˆ๋ฐ˜ ์ •๋„์— ๋ถˆ๊ณผํ•ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๋ฌธ์ œ์— ๋Œ€ํ•œ ์ธ์‹์ด ์ ์ฐจ ํ™•์‚ฐ๋˜๋ฉด์„œ ์ด๋ฅผ ํ•ด๊ฒฐํ•˜๋Š”๋ฐ ์œ ๋งํ•œ ์ฒœ์—ฐ ์ œํ’ˆ์ด๋‚˜ ๊ธฐํƒ€ ๋ณด์™„ ์น˜๋ฃŒ ๋ฐ ๋Œ€์•ˆ ์น˜๋ฃŒ(CAM)์— ๋Œ€ํ•œ ์—ฐ๊ตฌ๊ฐ€ ๋Œ€๋‘๋˜๊ฒŒ ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€์˜ ์ƒ๋ฆฌ ํ™œ์„ฑ ๋ฌผ์งˆ์€ ๋„ํŒŒ๋ฏผ๊ณผ ๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ์˜ ์žฌํก์ˆ˜ ์–ต์ œ ์ž‘์šฉ์„ ์ฆ์ง„์‹œํ‚ฌ ์ˆ˜ ์žˆ์œผ๋ฉฐ, N-๋ฉ”ํ‹ธ D-์•„์ŠคํŒŒ๋ฅดํŠธ์‚ฐ(NMDA) ์ˆ˜์šฉ์ฒด ๊ธธํ•ญ์ œ์™€ GABA ์ž‘์šฉ์ œ๋กœ์˜ ๊ธฐ๋Šฅ๋„ ๋ฐœํœ˜ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ด ๋‘ ๊ฐ€์ง€ ๋ฉ”์ปค๋‹ˆ์ฆ˜์€ ์ฃผ์˜๋ ฅ ๊ฒฐ์—ฌ ์ฆ์ƒ์— ์œ ์ตํ•œ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ์Šต๋‹ˆ๋‹ค. ์–ด๋ฆฐ์ด์™€ ์„ฑ์ธ ADHA ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ์‹ค์‹œํ•œ 6์ฃผ๊ฐ„์˜ ๋ฌด์ž‘์œ„ ์ด์ค‘ ๋งน๊ฒ€ ์ž„์ƒ ์กฐ์‚ฌ ๊ฒฐ๊ณผ, (ํ•˜๋ฃจ 20-30 mg์˜) ์‚ฌํ”„๋ž€์€ (ํ•˜๋ฃจ 20-30 mg์˜) ๋ฉ”ํ‹ธํŽ˜๋‹ˆ๋ฐ์ดํŠธ์™€ ๋™๋“ฑํ•œ ํšจ๊ณผ๋ฅผ ๋ณด์˜€์Œ์ด ํ•™๋ถ€๋ชจ์™€ ๊ต์‚ฌ์˜ ์„ค๋ฌธ ์กฐ์‚ฌ๋ฅผ ํ†ตํ•ด ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋ฅผ ์˜ˆ๋น„ ๋ฐ์ดํ„ฐ๋กœ ์‚ผ์•„ ์žฅ๊ธฐ์ ์œผ๋กœ ์ง„ํ–‰๋˜๋Š” ๋Œ€๊ทœ๋ชจ์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์‹œํ—˜์„ ์‹œํ–‰ํ•˜์—ฌ ์ด๋ฅผ ํ™•์ธํ•˜๋Š” ์ž‘์—…์ด ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€๊ณผ ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜

ํ˜„๋Œ€์— ๋ฐœํ‘œ๋˜๋Š” ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋Š” ์‚ฌํ”„๋ž€์ด ๊ฑด๊ฐ•ํ•œ ์‚ฌ๋žŒ์˜ ์ธ์ง€ ๊ธฐ๋Šฅ์„ ์ฆ์ง„ํ•˜๊ณ  ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜(AD) ํ™˜์ž์˜ ์ธ์ง€ ์žฅ์•  ์ฆ์ƒ์„ ์™„ํ™”ํ•œ๋‹ค๊ณ  ํ•˜๋Š” ์˜ค๋ž˜๋œ ์ „ํ†ต ์˜ํ•™์˜ ์ฃผ์žฅ์„ ๋’ท๋ฐ›์นจํ•ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์‚ฌํ”„๋ž€์˜ ์ธ์ง€ ์ฆ์ง„ ํšจ๊ณผ๋Š” ํ•ญ์‚ฐํ™”์ œ์™€ ํ•ญ ์•„๋ฐ€๋กœ์ด๋“œ ํ™œ์„ฑ์— ์˜ํ•ด ๋งค๊ฐœ๋˜๋Š” ๊ฒƒ์œผ๋กœ ์ƒ๊ฐ๋œ๋‹ค. ์•Œ์ธ ํ•˜์ด๋ฉฐ ํ™˜์ž์— ๋Œ€ํ•œ ์‚ฌํ”„๋ž€์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ์—์„œ๋Š” ์ผ๊ด€์ ์ธ ์ธ์ง€ ๋Šฅ๋ ฅ ํ–ฅ์ƒ์ด ๋ณด๊ณ ๋ฉ๋‹ˆ๋‹ค. ๊ฐ€๋ฒผ์šด ์•Œ์ธ ํ•˜์ด๋จธ ํ™˜์ž 55๋ช…์„ ๋Œ€์ƒ์œผ๋กœ 22์ฃผ๊ฐ„ ์‹ค์‹œํ•œ ์œ„์•ฝ ๋Œ€์กฐ ์‹œํ—˜์—์„œ๋Š” ์‚ฌํ”„๋ž€ (15mg์”ฉ 1์ผ 2ํšŒ)๊ณผ ์ฝœ๋ฆฐ์—์Šคํ…Œ๋ฅด ์–ต์ œ์ œ๋กœ ๋„๋ฆฌ ์ฒ˜๋ฐฉ๋˜๋Š” ์น˜๋ฃŒ ์•ฝ๋ฌผ์ธ ๋„๋„คํŽ˜์งˆ(5mg์”ฉ 1 ์ผ 2 ํšŒ)์„ ํ™˜์ž์—๊ฒŒ ๋ฌด์ž‘์œ„๋กœ ํˆฌ์—ฌํ•˜๊ณ , ํ‘œ์ค€ ์ฆ์ƒ ๋“ฑ๊ธ‰ ์กฐ์‚ฌ๋ฅผ ์‹ค์‹œํ•œ ๊ฒฐ๊ณผ ํ–‰๋™๊ณผ ์ธ์ง€ ๊ธฐ๋Šฅ์— ์žˆ์–ด ๋‘ ์•ฝ๋ฌผ์ด ๋™๋“ฑํ•œ ํ–ฅ์ƒ ํšจ๊ณผ๋ฅผ ๋ณด์˜€์Œ์ด ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜์˜ ๋™๋ฐ˜ ์งˆํ™˜์œผ๋กœ ์šฐ์šธ์ฆ์ด ๋งŽ์ด ๋”ฐ๋ผ์˜จ๋‹ค๋Š” ์‚ฌ์‹ค ์—ญ์‹œ ์‚ฌํ”„๋ž€์„ ํ•ฉ๋ฆฌ์ ์ธ ์น˜๋ฃŒ์ œ๋กœ ์„ ํƒํ•˜๊ฒŒ ๋งŒ๋“œ๋Š” ๋˜ ๋‹ค๋ฅธ ์ด์œ ์— ํ•ด๋‹นํ•ฉ๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€๊ณผ ๋ถˆ์•ˆ์ฆ, ์กฐํ˜„๋ณ‘ ๊ทธ๋ฆฌ๊ณ  ๊ฐ•๋ฐ• ์žฅ์• 

์šฐ์šธ์ฆ๊ณผ ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜, ๊ทธ๋ฆฌ๊ณ  ADHD์— ๋Œ€ํ•œ ์œ ์ตํ•œ ํšจ๊ณผ ์™ธ์—๋„ ์‚ฌํ”„๋ž€์€ ๋ถˆ์•ˆ ์žฅ์• ์™€ ์ •์‹ ๋ณ‘ ๋ฐ ๊ฐ•๋ฐ• ์žฅ์•  (OCD)์˜ ์ฆ์ƒ์— ์œ ์ตํ•œ ํšจ๊ณผ๊ฐ€ ์žˆ์„ ์ˆ˜ ์žˆ๋‹ค๋Š” ๋™๋ฌผ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๊ฐ€ ๋ฐœํ‘œ๋œ ๋ฐ” ์žˆ์Šต๋‹ˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ํ˜„์žฌ๊นŒ์ง€ ์ด๋Ÿฌํ•œ ์งˆํ™˜์— ๋Œ€ํ•œ ์‚ฌํ”„๋ž€์˜ ํšจ๊ณผ๋ฅผ ์กฐ์‚ฌํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ์ธ๊ฐ„์„ ๋Œ€์ƒ์œผ๋กœ ์‹ค์‹œํ•œ ์ž„์ƒ ์—ฐ๊ตฌ๋Š” ์—†์Šต๋‹ˆ๋‹ค. ์‚ฌํ”„๋ž€์˜ ์ƒ์ฒด ํ™œ์„ฑ ์„ฑ๋ถ„์ด ํ•ญ์šฐ์šธ ์ฆ์ƒ๊ณผ ์ •์‹ ๋ณ‘, ๊ทธ๋ฆฌ๊ณ  ๊ฐ•๋ฐ• ์žฅ์• ์— ๊ด€์—ฌํ•˜๋Š” ๋ฉ”์ปค๋‹ˆ์ฆ˜์€ ์•„์ง ๋ฐํ˜€์ง€์ง€ ์•Š์•˜์œผ๋‚˜, GABA-A์™€ NMDA ์‹ ๊ฒฝ ์ „๋‹ฌ ๋ฌผ์งˆ ์‹œ์Šคํ…œ์˜ ์กฐ์ ˆ์ด ํฌํ•จ๋˜์–ด ์žˆ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์‚ฌํ”„๋ž€๊ณผ ํ•ญ์‚ฐํ™”์ œ, ๊ทธ๋ฆฌ๊ณ  ์‹ ๊ฒฝ ๋ณดํ˜ธ ๊ธฐ๋Šฅ

๊ธฐ์กด์˜ ์ •์‹  ๊ฑด๊ฐ• ์งˆํ™˜ ์น˜๋ฃŒ๋ฒ•์˜ ํ•œ๊ณ„๋Š” ๋‹ค์–‘ํ•œ ๋ณด์™„ ๋Œ€์ฒด ์˜ํ•™ (CAM) ์น˜๋ฃŒ๋ฒ•์— ๋Œ€ํ•œ ์—ฐ๊ตฌ๋ฅผ ์ด‰์ง„์‹œํ‚ค๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ตœ๊ทผ ๋‹ค์–‘ํ•œ ๋น„์•ฝ๋ฆฌํ•™์  ๋ฐฉ๋ฒ• ์ค‘์—์„œ๋„ ์‚ฌํ”„๋ž€์˜ ์‹ ๊ฒฝ ์ •์‹  ์งˆํ™˜ ์น˜๋ฃŒ ํšจ๊ณผ์— ๊ด€์‹ฌ์ด ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๋Š” ์ถ”์„ธ์ž…๋‹ˆ๋‹ค. ์‚ฌํ”„๋ž€์— ๋Œ€ํ•œ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋Š” ์‚ฌํ”„๋ž€์ด ์ƒ๋‹นํ•œ ํ•ญ์‚ฐํ™”์ œ ํšจ๊ณผ์™€ ํ•ญ์‚ฐํ™”์ œ ํšจ๊ณผ ๋ฐ ์‹ ๊ฒฝ ๋ณดํ˜ธ ํšจ๊ณผ๋ฅผ ๋‚˜ํƒ€๋‚ด๋ฉฐ ๊ฒฝ์ฆ์—์„œ ์ค‘๋“ฑ๋„์˜ ์šฐ์šธ์ฆ๊ณผ ์•Œ์ธ ํ•˜์ด๋จธ ์งˆํ™˜์— ๋Œ€ํ•œ ์•ˆ์ „ํ•˜๊ณ  ํšจ๊ณผ์ ์ธ ์น˜๋ฃŒ๋ฒ•์ด๋ผ๋Š” ์‚ฌ์‹ค์„ ๋’ท๋ฐ›์นจํ•ฉ๋‹ˆ๋‹ค. ์ตœ๊ทผ ์—ฐ๊ตฌ์— ์˜ํ•˜๋ฉด ์‚ฌํ”„๋ž€์€ ADHD ์น˜๋ฃŒ์— ์‚ฌ์šฉ๋˜๋Š” ์ž๊ทน์ œ์™€ ๋น„๊ตํ• ๋งŒํ•œ ํšจ๋Šฅ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค๊ณ  ํ•ฉ๋‹ˆ๋‹ค. ์ „์ž„์ƒ ๋‹จ๊ณ„์˜ ๋™๋ฌผ ์—ฐ๊ตฌ์—์„œ ๋ฐํ˜€์ง„ ๊ธฐ์ดˆ ๋ฐ์ดํ„ฐ๋Š” ์‚ฌํ”„๋ž€์€ ๋ถˆ์•ˆ์ฆ๊ณผ ์ •์‹  ์งˆํ™˜, ๊ทธ๋ฆฌ๊ณ  ๊ฐ•๋ฐ• ์žฅ์•  ์น˜๋ฃŒ์ œ๋กœ ์ƒ๋‹นํ•œ ํšจ๋Šฅ์„ ๋ฐœํœ˜ํ•  ์ˆ˜ ์žˆ์Œ์„ ์‹œ์‚ฌํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์œ„์˜ ๊ฒฐ๊ณผ๋ฅผ ํ™•์ธํ•˜๊ณ , ์‚ฌํ”„๋ž€์„ ๋‹ค๋ฅธ ์ฒœ์—ฐ ์ œํ’ˆ์ด๋‚˜ ์ •์‹  ์งˆํ™˜ ์น˜๋ฃŒ์ œ์™€ ๋ณ‘์šฉํ•  ๊ฒฝ์šฐ, ์ตœ์ ์˜ ๋ณต์šฉ๋Ÿ‰๊ณผ ์•ˆ์ „์„ฑ์„ ํ™•๋ฆฝํ•˜๋ ค๋ฉด ์žฅ๊ธฐ์ ์œผ๋กœ ์ง„ํ–‰๋˜๋Š” ๋Œ€๊ทœ๋ชจ์˜ ์œ„์•ฝ ๋Œ€์กฐ ์ž„์ƒ ์‹œํ—˜์„ ์‹œํ–‰ํ•  ํ•„์š”๊ฐ€ ์žˆ์Šต๋‹ˆ๋‹ค.

์ฐธ๊ณ  ๋ฌธํ—Œ:

  1. Akhondzadeh Basti A, Moshiri E, Noorbala A-A, Jamshidi A-H, Abbasi SH, Akhondzadeh S: Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 31:439–442, 2007.
  2. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi AH, Zare F, Moradi A (2009) Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo controlled trial. J Clin Pharm Ther
  3. Akhondzadeh, S. et al, A22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease, Psychopharmacology (2010) 207:637–643
  4. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008 Dec 10;(12):1-23.
  5. Baziar, S., Aqamolaei, A., Khadem, E., Mortazavi, S., Naderi, S. et al (2019) Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. J Child Adolesc Psychopharmacol. 29:3; 1-8.
  6. Berman SM, et al. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14(2):123–42.
  7. Denys, D., de Haan, L., (2008) [25 years antipsychotics: back to the future?] [Article in Dutch] Tijdschr Psychiatr. 2008;50 Spec no.:105-9.
  8. Fernandez JA (2004) Biology, biotechnology and biomedicine of saffron. Recent Res Dev Plant Sci 2:127–159.
  9. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010 Jan 6;303(1):47-53.
  10. Georgiadou G, Tarantilis PA, Pitsikas N. Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive-compulsive disorder. Neurosci Lett. 2012 Oct 18;528(1):27-30.
  11. Hartling L, Abu-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: Comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-analysis. Ann Intern Med 2012 Oct 2;157(7):498-511.
  12. Herrmann N, Chau SA, Kircanski I, Lanctôt KL. (2011) Current and emerging drug treatment options for Alzheimer’s disease: A systematic review. Drugs 22;71(15):2031- 65.
  13. Kanchanatawan B, Tangwongchai S, Sughondhabhirom A, Suppapitiporn S, Hemrunrojn S, Carvalho AF, Maes M. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. Neurotox Res. 2018 Apr;33(3):621-633.
  14. Kelley J. (2 March 2010) Antidepressants: Do they “work” or don’t they? [Internet]. New York, NY: Scientific American; 2010 Mar 2
  15. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. (2008) Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5(2):e45.
  16. Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J Affect Disord. 2017 Jan 1;207:188-196.
  17. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014 Nov;29(6):517-27.
  18. Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2014;167:368-75.
  19. Negbi M (1999) Saffron cultivation: past, present and future prospects. In: Negbi M (ed) Saffron Crocus sativus L. Harwood, Amsterdam, pp 1–17.
  20. Newcorn JH, et al. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr. 2007;12(8 Suppl 12):1–14.
  21. Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis P, Margarity M, Lamari FN (2006) Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 15:8762–8768
  22. Pitsikas N, Boultadakis A, Georgiadou G, Tarantilis PA, Sakellaridis N: Effects of the active constituents of Crocus sativus L., crocins, in an animal model of anxiety. Phytomedicine 15:1135–1139, 2008.
  23. Pitsikas N, Sakellaridis N: Crocus sativus L. extracts antagonize memory impairments in different behavioural tasks in the rat. Behav Brain Res 173:112–115, 2006.
  24. Pitsikas, N., Constituents of Saffron (Crocus sativus L.) as Potential Candidates for the Treatment of Anxiety Disorders and Schizophrenia Molecules. 2016 Mar; 21(3): 303.
  25. Rฤฑ´os JL, Recio MC, Giner RM, Ma´n˜ez S: An update review of saffron and its active constituents. Phytother Res 10:189–193, 1996.
  26. Schachter HM, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. 2001;165(11):1475–88.
  27. Schmidt M, Betti G, Hensel A (2007) Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 157:315–319
  28. Srivastava R, Ahmed H, Dixit RK, Dharamveer, Saraf SA: Crocus sativus L.: A comprehensive review. Pharmacogn Rev 4:200–208, 2010.
  29. Stafford MR, Mayo-Wilson E, Loucas CE, et al. 2015 Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: A systematic review and meta-analysis. PloS One Feb 11;10(2):e0117166.
  30. Thase ME. STEP-BD and bipolar depression: What have we learned? Curr Psychiatry Rep 2007 Dec;9(6):497-503.
  31. Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, Tenk J, Pétervári E, Balaskó M, Rumbus Z, Rakonczay Z, Bálint ER, Kiss T, Csupor D. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. Planta Med. 2019 Jan;85(1):24-31.
  32. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46.
  33. Wang et al (2010) Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J Nat Med (2010) 64:24–30.
  34. Wang Y, Han T, Zhu Y, Zheng CJ, Ming QL, Rahman K, Qin LP: Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J Nat Med 64:24–30, 2010.
  35. Xuabin N (1992) Research progresses on the saffron crocus (Crocus sativus). Zhongcaoyao 23:100–107.

๋ฉด์ฑ…์‚ฌํ•ญ:์›ฐ๋‹ˆ์Šค ํ—ˆ๋ธŒ์˜ ์ทจ์ง€๋Š” ์˜ํ•™์ ์ธ ์ง„๋‹จ์ด๋‚˜ ์น˜๋ฃŒ๋ฅผ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์ด ์•„๋‹™๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ